| Supervised risk predictor of breast cancer based on intrinsic subtypes JS Parker, M Mullins, MCU Cheang, S Leung, D Voduc, T Vickery, ... Journal of clinical oncology 27 (8), 1160, 2009 | 5108 | 2009 |
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study LA Carey, CM Perou, CA Livasy, LG Dressler, D Cowan, K Conway, ... Jama 295 (21), 2492-2502, 2006 | 5005 | 2006 |
| Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma TO Nielsen, FD Hsu, K Jensen, M Cheang, G Karaca, Z Hu, ... Clinical cancer research 10 (16), 5367-5374, 2004 | 3660 | 2004 |
| Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer MCU Cheang, SK Chia, D Voduc, D Gao, S Leung, J Snider, M Watson, ... JNCI: Journal of the National Cancer Institute 101 (10), 736-750, 2009 | 3076 | 2009 |
| Metastatic behavior of breast cancer subtypes H Kennecke, R Yerushalmi, R Woods, MCU Cheang, D Voduc, ... Journal of clinical oncology 28 (20), 3271-3277, 2010 | 2603 | 2010 |
| Breast cancer subtypes and the risk of local and regional relapse KD Voduc, MCU Cheang, S Tyldesley, K Gelmon, TO Nielsen, ... Journal of clinical oncology 28 (10), 1684-1691, 2010 | 1703 | 2010 |
| Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype MCU Cheang, D Voduc, C Bajdik, S Leung, S McKinney, SK Chia, ... Clinical cancer research 14 (5), 1368-1376, 2008 | 1685 | 2008 |
| Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 … FM Blows, KE Driver, MK Schmidt, A Broeks, FE Van Leeuwen, ... PLoS medicine 7 (5), e1000279, 2010 | 1246 | 2010 |
| Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer I Garcia-Murillas, G Schiavon, B Weigelt, C Ng, S Hrebien, RJ Cutts, ... Science translational medicine 7 (302), 302ra133-302ra133, 2015 | 1192 | 2015 |
| A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor–positive breast cancer TO Nielsen, JS Parker, S Leung, D Voduc, M Ebbert, T Vickery, SR Davies, ... Clinical cancer research 16 (21), 5222-5232, 2010 | 888 | 2010 |
| Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial A Tutt, H Tovey, MCU Cheang, S Kernaghan, L Kilburn, P Gazinska, ... Nature medicine 24 (5), 628-637, 2018 | 822 | 2018 |
| Prognostic significance of progesterone receptor–positive tumor cells within immunohistochemically defined luminal A breast cancer A Prat, MCU Cheang, M Martín, JS Parker, E Carrasco, R Caballero, ... Journal of clinical oncology 31 (2), 203, 2013 | 735 | 2013 |
| Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer A Prat, B Adamo, MCU Cheang, CK Anders, LA Carey, CM Perou The oncologist 18 (2), 123-133, 2013 | 719 | 2013 |
| Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial J Hugh, J Hanson, MCU Cheang, TO Nielsen, CM Perou, C Dumontet, ... Journal of clinical oncology 27 (8), 1168, 2009 | 698 | 2009 |
| Use of immunohistochemical markers can refine prognosis in triple negative breast cancer M Tischkowitz, JS Brunet, LR Bégin, DG Huntsman, MCU Cheang, ... BMC cancer 7, 1-11, 2007 | 563 | 2007 |
| Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers S Chia, B Norris, C Speers, M Cheang, B Gilks, AM Gown, D Huntsman, ... Journal of Clinical Oncology 26 (35), 5697-5704, 2008 | 435 | 2008 |
| Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus … LA Carey, DA Berry, CT Cirrincione, WT Barry, BN Pitcher, LN Harris, ... Journal of Clinical Oncology 34 (6), 542, 2016 | 397 | 2016 |
| Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ... Breast cancer research and treatment 132, 1049-1062, 2012 | 373 | 2012 |
| Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells BW Sutherland, J Kucab, J Wu, C Lee, MCU Cheang, E Yorida, D Turbin, ... Oncogene 24 (26), 4281-4292, 2005 | 365 | 2005 |
| Use of mutation profiles to refine the classification of endometrial carcinomas MK McConechy, J Ding, MCU Cheang, KC Wiegand, J Senz, AA Tone, ... The Journal of pathology 228 (1), 20-30, 2012 | 334 | 2012 |
Charles M. PerouUniversity of North Carolina at Chapel Hillبريد إلكتروني تم التحقق منه على med.unc.edu
